MARCKSL1 interacted with F-actin to promote esophageal squamous cell carcinoma mobility by modulating the formation of invadopodia.
Humans
Actins
/ metabolism
Calmodulin-Binding Proteins
/ genetics
Cell Line, Tumor
Cell Movement
/ genetics
Cell Proliferation
/ genetics
Cortactin
/ genetics
Esophageal Neoplasms
/ pathology
Esophageal Squamous Cell Carcinoma
/ genetics
Gene Expression Regulation, Neoplastic
Lymphatic Metastasis
Neoplasm Invasiveness
/ genetics
Podosomes
/ metabolism
MARCKSL1
esophageal cancer
invadopodia formation
metastasis
Journal
Cancer medicine
ISSN: 2045-7634
Titre abrégé: Cancer Med
Pays: United States
ID NLM: 101595310
Informations de publication
Date de publication:
02 2023
02 2023
Historique:
revised:
03
07
2022
received:
20
04
2022
accepted:
12
07
2022
pubmed:
28
7
2022
medline:
25
2
2023
entrez:
27
7
2022
Statut:
ppublish
Résumé
Emerging evidence indicates that myristoylated alanine-rich C kinase substrate like 1 (MARCKSL1) is involved in the progression of esophageal squamous cell carcinoma (ESCC). However, the underpinning mechanism is unclear. Here, we investigated the mechanisms involving MARCKSL1 in ESCC progression. CCK8, Transwell and wound-healing assays were employed to test the effect of MARCKSL1 on proliferation, invasion and migration in vitro. Next, transcriptome profiling was conducted through RNA sequencing to reveal the underlying mechanism of MARCKSL1 in ESCC progression, which was subsequently verified by western blot and qPCR analysis. Moreover, immunofluorescence and gelatin degradation assays were performed to reveal the ability of MARCKSL1 to mediate invadopodia formation and extracellular matrix (ECM) degradation. Finally, the correlation between MARCKSL1 and the clinicopathological features of ESCC patients was assessed based on TCGA database analysis and immunohistochemistry staining of tissue microarrays. Knockdown of MARCKSL1 markedly attenuated the cell motility capacity of ESCC cells in vitro, while MARCKSL1 overexpression had the opposite effect. Transcriptomic analysis showed that MARCKSL1 mediated the mobility and migration of ESCC cells. In addition, overexpression of MARCKSL1 increased the colocalization of F-actin and cortactin at the frontier edge of migrating cells and ECM degradation. Furthermore, in ESCC patients, the mRNA level of MARCKSL1 in esophageal carcinomas (n = 182) was found to be notably higher than that in adjacent esophageal epithelia (n = 286) and the expression levels of MARCKSL1 in the tumor tissues (n = 811) were significantly increased compared to those in noncancerous esophageal tissues (n = 442) with a large sample size. Higher expression of MARCKSL1 was positively correlated with lymph node metastasis and associated with worse survival rates of patients with ESCC. MARCKSL1 promotes cell migration and invasion by interacting with F-actin and cortactin to regulate invadopodia formation and ECM degeneration. High MARCKSL1 expression is positively correlated with poor prognosis in ESCC patients with lymph node metastasis.
Sections du résumé
BACKGROUND
Emerging evidence indicates that myristoylated alanine-rich C kinase substrate like 1 (MARCKSL1) is involved in the progression of esophageal squamous cell carcinoma (ESCC). However, the underpinning mechanism is unclear. Here, we investigated the mechanisms involving MARCKSL1 in ESCC progression.
METHODS
CCK8, Transwell and wound-healing assays were employed to test the effect of MARCKSL1 on proliferation, invasion and migration in vitro. Next, transcriptome profiling was conducted through RNA sequencing to reveal the underlying mechanism of MARCKSL1 in ESCC progression, which was subsequently verified by western blot and qPCR analysis. Moreover, immunofluorescence and gelatin degradation assays were performed to reveal the ability of MARCKSL1 to mediate invadopodia formation and extracellular matrix (ECM) degradation. Finally, the correlation between MARCKSL1 and the clinicopathological features of ESCC patients was assessed based on TCGA database analysis and immunohistochemistry staining of tissue microarrays.
RESULTS
Knockdown of MARCKSL1 markedly attenuated the cell motility capacity of ESCC cells in vitro, while MARCKSL1 overexpression had the opposite effect. Transcriptomic analysis showed that MARCKSL1 mediated the mobility and migration of ESCC cells. In addition, overexpression of MARCKSL1 increased the colocalization of F-actin and cortactin at the frontier edge of migrating cells and ECM degradation. Furthermore, in ESCC patients, the mRNA level of MARCKSL1 in esophageal carcinomas (n = 182) was found to be notably higher than that in adjacent esophageal epithelia (n = 286) and the expression levels of MARCKSL1 in the tumor tissues (n = 811) were significantly increased compared to those in noncancerous esophageal tissues (n = 442) with a large sample size. Higher expression of MARCKSL1 was positively correlated with lymph node metastasis and associated with worse survival rates of patients with ESCC.
CONCLUSION
MARCKSL1 promotes cell migration and invasion by interacting with F-actin and cortactin to regulate invadopodia formation and ECM degeneration. High MARCKSL1 expression is positively correlated with poor prognosis in ESCC patients with lymph node metastasis.
Identifiants
pubmed: 35894387
doi: 10.1002/cam4.5079
pmc: PMC9939165
doi:
Substances chimiques
Actins
0
Calmodulin-Binding Proteins
0
Cortactin
0
MARCKSL1 protein, human
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
3299-3312Informations de copyright
© 2022 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Références
Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394-424. doi:10.3322/caac.21492
Pennathur A, Gibson MK, Jobe BA, et al. Oesophageal carcinoma. Lancet. 2013;381:400-412. doi:10.1016/S0140-6736(12)60643-6
Chien HC, Chen HS, Wu SC, et al. The prognostic value of metastatic lymph node number and ratio in oesophageal squamous cell carcinoma patients with or without neoadjuvant chemoradiation. Eur J Cardiothorac Surg. 2016;50:337-343. doi:10.1093/ejcts/ezw016
El Amri M, Fitzgerald U, Schlosser G. MARCKS and MARCKS-like proteins in development and regeneration. J Biomed Sci. 2018;25:43. doi:10.1186/s12929-018-0445-1
Bjorkblom B, Padzik A, Mohammad H, et al. C-Jun N-terminal kinase phosphorylation of MARCKSL1 determines Actin stability and migration in neurons and in cancer cells. Mol Cell Biol. 2012;32:3513-3526. doi:10.1128/MCB.00713-12
Van Itallie CM, Tietgens AJ, Aponte A, et al. MARCKS-related protein regulates cytoskeletal organization at cell-cell and cell-substrate contacts in epithelial cells. J Cell Sci. 2018;131:1-14. doi:10.1242/jcs.210237
Yue L, Bao Z, Li J. Phosphorylated form of MacMARCKS is essential to LFA-1-dependent cell-cell adhesion of U937 monocytic cells. J Cell Physiol. 1999;181:355-360. doi:10.1002/(SICI)1097-4652(199911)181:2<355::AID-JCP17>3.0.CO;2-B
Wu M, Chen DF, Sasaoka T, et al. Neural tube defects and abnormal brain development in F52-deficient mice. Proc Natl Acad Sci USA. 1996;93:2110-2115. doi:10.1073/pnas.93.5.2110
Chen J, Chang S, Duncan SA, et al. Disruption of the MacMARCKS gene prevents cranial neural tube closure and results in anencephaly. Proc Natl Acad Sci USA. 1996;93:6275-6279. doi:10.1073/pnas.93.13.6275
Tanaka T, Shimizu S, Ueno M, et al. MARCKSL1 regulates spine formation in the amygdala and controls the hypothalamic-pituitary-adrenal Axis and anxiety-like behaviors. EBioMedicine. 2018;30:62-73. doi:10.1016/j.ebiom.2018.03.018
Kim BR, Dong SM, Seo SH, et al. Lysyl oxidase-like 2 (LOXL2) controls tumor-associated cell proliferation through the interaction with MARCKSL1. Cell Signal. 2014;26:1765-1773. doi:10.1016/j.cellsig.2014.05.010
Romanuik TL, Ueda T, Le N, et al. Novel biomarkers for prostate cancer including noncoding transcripts. Am J Pathol. 2009;175:2264-2276. doi:10.2353/ajpath.2009.080868
Chen Z, Liu Y, Yao L, et al. The long noncoding RNA lncZic2 drives the self-renewal of liver tumor-initiating cells via the protein kinase C substrates MARCKS and MARCKSL1. J Biol Chem. 2018;293:7982-7992. doi:10.1074/jbc.RA117.001321
Jonsdottir K, Zhang H, Jhagroe D, et al. The prognostic value of MARCKS-like 1 in lymph node-negative breast cancer. Breast Cancer Res Treat. 2012;135(2):381-390.
Karagoz K, Lehman HL, Stairs DB, Sinha R, Arga KY. Proteomic and metabolic signatures of esophageal squamous cell carcinoma. Curr Cancer Drug Targets. 2016;16:721-736.
Hao XP, Pretlow TG, Rao JS, et al. Beta-catenin expression is altered in human colonic aberrant crypt foci. Cancer Res. 2001;61(22):8085-8088.
Ye B, Fan D, Xiong W, et al. Oncogenic enhancers drive esophageal squamous cell carcinogenesis and metastasis. Nat Commun. 2021;12(1):4457. doi:10.1038/s41467-021-24813-2
Liu G, Bao Y, Liu C, et al. IKKε phosphorylates kindlin-2 to induce invadopodia formation and promote colorectal cancer metastasis. Theranostics. 2020;10(5):2358-2373. doi:10.7150/thno.40397
Egeland NG, Austdal M, van Diermen-Hidle B, et al. Validation study of MARCKSL1 as a prognostic factor in lymph node-negative breast cancer patients. PLoS One. 2019;14(3):e0212527. doi:10.1371/journal.pone.0212527
Liang W, Gao R, Yang M, et al. MARCKSL1 promotes the proliferation, migration and invasion of lung adenocarcinoma cells. Oncol Lett. 2020;19:2272-2280. doi:10.3892/ol.2020.11313